Safety and efficacy of contraception-Why should the obese woman be any different?

Reviews in Endocrine and Metabolic Disorders

Volumn 12, Issue 2, 2011, Pages 85-91

  Rodriguez, Maria I ^a   Edelman, Alison B ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

BMI; Contraception; Obesity; Unintended pregnancy

Indexed keywords

CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE; STEROID HORMONE; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENESIS; BODY FAT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINED HORMONAL CONTRACEPTION; COMBINED ORAL CONTRACEPTION; CONDOM; CONTRACEPTION; COUNSELING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCOSE METABOLISM; HORMONAL CONTRACEPTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; IMPLANT; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID METABOLISM; OBESITY; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PILL; PLETHYSMOGRAPHY; PREGNANCY COMPLICATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY; TRANSDERMAL PATCH; TRIACYLGLYCEROL BLOOD LEVEL; UNPLANNED PREGNANCY; VAGINA RING; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANIMALS; CONTRACEPTION; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; OBESITY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY, UNPLANNED; YOUNG ADULT;

EID: 79958094979     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-011-9181-5     Document Type: Article

References (57)

1. A Edelman 2009 Society of family planning clinical guidelines: contraceptive considerations in obese women Contraception. 80 7 10.1016/j.contraception.2009.02.005
2. SO Skouby 2010 Hormonal contraception in obesity, the metabolic syndrome, and diabetes Ann N Y Acad Sci. 1205 240 4 10.1111/j.1749-6632.2010.05662.x 20840279 10.1111/j.1749-6632.2010.05662.x
3. LB Finer SK Henshaw 2006 Disparities in rates of unintended pregnancy in the United States, 1994 and 2001 Perspect Sex Reprod Health. 38 2 90 6 10.1363/psrh.38.090.06 16772190 10.1363/3809006 (Pubitemid 43882311)
4. C Dehlendorf MI Rodriguez K Levy S Borrero J Steinauer 2010 Disparities in family planning Am J Obstet Gynecol. 202 3 214 20 10.1016/j.ajog.2009.08.022 20207237 10.1016/j.ajog.2009.08.022
5. KM Rasmussen B Abrams LM Bodnar NF Butte PM Catalano A Maria Siega-Riz 2010 Recommendations for weight gain during pregnancy in the context of the obesity epidemic Obstet Gynecol. 116 5 1191 5 10.1097/AOG.0b013e3181f60da7 20966705 10.1097/AOG.0b013e3181f60da7
6. GA Davies C Maxwell L McLeod R Gagnon M Basso H Bos, et al. 2010 Obesity in pregnancy J Obstet Gynaecol Can. 32 2 165 73 20181319
7. CM Boney A Verma R Tucker BR Vohr 2005 Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus Pediatrics. 115 3 e290 6 10.1542/peds.2004-1808 15741354 10.1542/peds.2004-1808 (Pubitemid 43373011)
8. N Xita A Tsatsoulis 2010 Fetal origins of the metabolic syndrome Ann N Y Acad Sci. 1205 148 55 10.1111/j.1749-6632.2010.05658.x 20840267 10.1111/j.1749-6632.2010.05658.x
9. AB Edelman NE Carlson G Cherala MY Munar RL Stouffer JL Cameron, et al. 2009 Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity Contraception. 80 2 119 27 10.1016/j.contraception.2009.04.011 19631786 10.1016/j.contraception.2009.04.011 1:CAS:528:DC%2BD1MXovF2rtbg%3D
10. Organization WH. BMI categories. 2011. http://www.euro.who.int/. Accessed January 22, 2011.
11. IF Godsland D Crook R Simpson T Proudler C Felton B Lees, et al. 1990 The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism N Engl J Med. 323 20 1375 81 10.1056/NEJM199011153232003 2146499 10.1056/NEJM199011153232003 1:CAS:528:DyaK3MXkvVGlsr0%3D
12. BA Frempong M Ricks S Sen AE Sumner 2008 Effect of low-dose oral contraceptives on metabolic risk factors in African-American women J Clin Endocrinol Metab. 93 6 2097 103 10.1210/jc.2007-2599 18334585 10.1210/jc.2007-2599 1:CAS:528:DC%2BD1cXntFamsbY%3D (Pubitemid 351831521)
13. A Teichmann 1995 Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel Int J Fertil Menopausal Stud. 40 Suppl 2 98 104 8574257
14. MR Adams TB Clarkson CA Shively JS Parks JR Kaplan 1990 Oral contraceptives, lipoproteins, and atherosclerosis Am J Obstet Gynecol. 163 4 Pt 2 1388 93 2220963 1:CAS:528:DyaK3MXhtFGis7g%3D (Pubitemid 20369745)
15. TB Clarkson CA Shively TM Morgan DR Koritnik MR Adams JR Kaplan 1990 Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys Obstet Gynecol. 75 2 217 22 2300348 1:STN:280:DyaK3c7jslKrtA%3D%3D (Pubitemid 20062237)
16. RB Machado NR de Melo H Maia Jr AM Cruz 2010 Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles Contraception. 81 2 102 6 10.1016/j.contraception.2009.08.009 20103445 10.1016/j.contraception.2009.08.009 1:CAS:528:DC%2BC3cXjslamsQ%3D%3D
17. S Song JK Chen PJ Yang ML He LM Li BC Fan, et al. 1992 A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel Contraception. 45 6 523 32 1535580 10.1016/0010-7824(92)90103-Z 1:STN:280:DyaK38zhsFKmtA%3D%3D
18. UH Winkler R Sudik 2009 The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters Contraception 79 1 15 23 10.1016/j.contraception.2008.08.011 19041436 10.1016/j.contraception.2008.08.011 1:CAS:528:DC%2BD1cXhsVers77L
19. Machado RB, de Melo NR, Maia H Jr, Cruz AM. Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles. Contraception. 81(2):102-6. doi: 10.1016/j.contraception.2009.08.009.
20. HB Croxatto 2000 Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant Eur J Contracept Reprod Health Care. 5 Suppl 2 21 8 11246604 1:CAS:528:DC%2BD3MXitFCis78%3D (Pubitemid 32171234)
21. Dilbaz B, Ozdegirmenci O, Caliskan E, Dilbaz S, Haberal A. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception. 81(6):510-4. doi: 10.1016/j.contraception.2010.01.014.
22. F Kayikcioglu M Gunes O Ozdegirmenci A Haberal 2006 Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study Contraception. 73 5 528 31 10.1016/j.contraception.2005. 12.005 16627040 10.1016/j.contraception.2005.12.005 1:CAS:528: DC%2BD28Xjs1WqsL4%3D
23. R Kongsayreepong S Chutivongse P George S Joyce JM McCone J Garza-Flores, et al. 1993 A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction Contraception. 47 2 177 91 8449018 10.1016/0010-7824(93)90090-T 1:STN:280:DyaK3s7ptlCnuw%3D%3D (Pubitemid 23062257)
24. HS Kahn KM Curtis PA Marchbanks 2003 Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk Diabetes Care. 26 1 216 25 12502684 10.2337/diacare.26.1.216 1:CAS:528:DC%2BD3sXms1aisQ%3D%3D (Pubitemid 36929020)
25. MJ Rosenberg MS Waugh 1998 Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons Am J Obstet Gynecol. 179 3 Pt 1 577 82 9757954 10.1016/S0002-9378(98)70047-X 1:STN:280:DyaK1cvivV2hsw%3D%3D (Pubitemid 28447229)
26. Lopez LM, Grimes DA, Chen-Mok M, Westhoff C, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2010;(7):CD008452. doi: 10.1002/14651858.CD008452.pub2.
27. Hormonal contraceptives for contraception in overweight or obese women. Obstet Gynecol. 2010; 116(5):1206-7. doi: 10.1097/AOG.0b013e3181f81ccf.
28. CM Picardo M Nichols A Edelman JT Jensen 2003 Women's knowledge and sources of information on the risks and benefits of oral contraception J Am Med Womens Assoc. 58 2 112 6 12744425
29. MF Gallo DA Grimes KF Schulz FM Helmerhorst 2004 Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials Obstet Gynecol. 103 2 359 73 10.1097/01.AOG. 0000107298.29343.6a 14754709 10.1097/01.AOG.0000107298.29343.6a 1:CAS:528:DC%2BD2cXhslGnsr4%3D
30. KJ O'Connell LM Osborne C Westhoff 2005 Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive Contraception. 72 5 323 7 10.1016/j.contraception.2005.05.008 16246655 10.1016/j.contraception.2005.05.008 (Pubitemid 41503126)
31. AB Edelman G Cherala FZ Stanczyk 2010 Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review Contraception. 82 4 314 23 10.1016/j.contraception.2010.04.016 20851224 10.1016/j.contraception.2010.04.016 1:CAS:528:DC%2BC3cXhtFOnsLfJ
32. M Ronnerdag V Odlind 1999 Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use Acta Obstet Gynecol Scand. 78 8 716 21 10468065 10.1080/j.1600-0412.1999.780810.x 1:STN:280:DyaK1Mzps1Wnsw%3D%3D (Pubitemid 29392677)
33. Y Linne L Dye B Barkeling S Rossner 2003 Weight development over time in parous women-the SPAWN study-15 years follow-up Int J Obes Relat Metab Disord. 27 12 1516 22 10.1038/sj.ijo.0802441 14634683 10.1038/sj.ijo.0802441 1:STN:280:DC%2BD3srlsVajtQ%3D%3D (Pubitemid 38019165)
34. O Kiriwat A Patanayindee S Koetsawang T Korver HJ Bennink 1998 A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand Eur J Contracept Reprod Health Care. 3 2 85 91 9710712 10.3109/13625189809051409 1:CAS:528: DyaK1cXlsFWrt7s%3D (Pubitemid 128690533)
35. S Funk MM Miller DR Mishell Jr DF Archer A Poindexter J Schmidt, et al. 2005 Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel Contraception. 71 5 319 26 10.1016/j.contraception.2004. 11.007 15854630 10.1016/j.contraception.2004.11.007 1:CAS:528: DC%2BD2MXjs1Gisbw%3D (Pubitemid 40602307)
36. M Pantoja T Medeiros MC Baccarin SS Morais L Bahamondes AM Fernandes 2010 Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive Contraception. 81 2 107 11 10.1016/j.contraception.2009.07.008 20103446 10.1016/j.contraception.2009.07.008 1:CAS:528:DC%2BC3cXjslamtg%3D%3D
37. AE Bonny J Ziegler R Harvey SM Debanne M Secic BA Cromer 2006 Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method Arch Pediatr Adolesc Med. 160 1 40 5 10.1001/archpedi.160.1.40 16389209 10.1001/archpedi.160. 1.40 (Pubitemid 43042133)
38. AE Bonny LS Harkness BA Cromer 2005 Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female Adolesc Med Clin. 16 3 569 84 10.1016/j.admecli.2005.05.006 16183540 10.1016/j.admecli.2005.05.006 (Pubitemid 41393018)
39. AB Berenson M Rahman 2009 Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use Am J Obstet Gynecol. 200 3 329 e1 8 10.1016/j.ajog.2008.12.052 10.1016/j.ajog.2008.12.052
40. Lopez L EA, Chen-Mok M, Trussell J, Helmerhorst F. Progestin-only contraceptives: effecs on weight. Cochrane Database of Systematic Reviews. 2011(11- In Press).
41. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep. 59(RR-4):1-86.
42. DA Grimes WC Shields 2005 Family planning for obese women: challenges and opportunities Contraception. 72 1 1 4 10.1016/j.contraception.2005.04.002 15964284 10.1016/j.contraception.2005.04.002 (Pubitemid 40827110)
43. LA Heinemann JC Dinger 2007 Range of published estimates of venous thromboembolism incidence in young women Contraception. 75 5 328 36 10.1016/j.contraception.2006.12.018 17434013 10.1016/j.contraception.2006.12.018 (Pubitemid 46551070)
44. S Higginbotham 2009 Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091 Contraception. 80 6 583 90 10.1016/j.contraception.2009.08.001 19913155 10.1016/j.contraception.2009.08.001
45. M Abdollahi M Cushman FR Rosendaal 2003 Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use Thromb Haemost. 89 3 493 8 10.1267/THRO03030493 12624633 1:CAS:528:DC%2BD3sXitlSktLk%3D (Pubitemid 36329240)
46. ACOG Practice Bulletin. The use of hormonal contraception in women with coexisting medical conditions. Number 18, July 2000. Int J Gynaecol Obstet. 2001; 75(1):93-106.
47. ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 115(1):206-18. doi: 10.1097/AOG. 0b013e3181cb50b5.
48. KM Rager HA Omar 2005 Hormonal contraception: noncontraceptive benefits and medical contraindications Adolesc Med Clin. 16 3 539 51 10.1016/j.admecli. 2005.05.003 16183538 10.1016/j.admecli.2005.05.003 (Pubitemid 41393016)
49. B Kaneshiro JT Jensen NE Carlson SM Harvey MD Nichols AB Edelman 2008 Body mass index and sexual behavior Obstet Gynecol. 112 3 586 92 10.1097/AOG.0b013e31818425ec 18757656 10.1097/AOG.0b013e31818425ec
50. Speroff L. Clinical gynecologic endocrinology and infertility. 6th ed. Baltimore: Lippencott Williams & Wilkins; 1999.
51. Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol. 117(1):33-40.
52. JC Dinger M Cronin S Mohner I Schellschmidt TD Minh C Westhoff 2009 Oral contraceptive effectiveness according to body mass index, weight, age, and other factors Am J Obstet Gynecol. 201 3 263 e1 9 10.1016/j.ajog.2009.03.017 10.1016/j.ajog.2009.03.017
53. L Potter D Oakley E de Leon-Wong R Canamar 1996 Measuring compliance among oral contraceptive users Fam Plann Perspect. 28 4 154 8 8853280 10.2307/2136191 1:STN:280:DyaK2s%2FgsF2rtw%3D%3D (Pubitemid 26256700)
54. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception. 82(4):314-23. doi: 10.1016/j.contraception.2010.04.016.
55. Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception. 81(6):474-80. doi: 10.1016/j.contraception.2010.01.016.
56. J Jain AJ Jakimiuk FR Bode D Ross AM Kaunitz 2004 Contraceptive efficacy and safety of DMPA-SC Contraception. 70 4 269 75 10.1016/j.contraception.2004. 06.011 15451329 10.1016/j.contraception.2004.06.011 1:CAS:528: DC%2BD2cXnvV2rsL4%3D (Pubitemid 39286760)
57. LR Brunner Huber CJ Hogue 2005 The association between body weight, unintended pregnancy resulting in a livebirth, and contraception at the time of conception Matern Child Health J. 9 4 413 20 16235025 10.1007/s10995-005-0015-5 10.1007/s10995-005-0015-5 (Pubitemid 43337505)